Customer receives a non-exclusive, non-transferable license for use of the Product, Progeny (meaning any unmodified descendant form of the Product), Modifications (meaning any modifications of the Product) and Unmodified Derivatives (meaning any substances created by the Customer which constitute an unmodified functional subunit or product expressed by the Product) for RESEARCH USE ONLY, which, subject to the exclusions below, includes use to discover and develop any product, including therapeutic products, which may then be sold to third parties, provided, however, that such products do not incorporate the Product, Progeny, Modifications, or Unmodified Derivatives.
No “Commercial Use” is allowed. Commercial Use means any and all uses of the Product, Progeny, Modifications or Unmodified Derivatives thereof, or any modified cells or organisms created through use of the foregoing, by the Customer for monetary or other consideration, including but not limited to:
- Sale or transfer, whether or not such sale or transfer is limited for use in research;
- Provision of a service to a third party;
- Use in any diagnostic, preventative, or therapeutic application;
- Use in any veterinary, livestock or agricultural application;
- Use in screening or profiling of more than 10,000 distinct compounds per calendar year (high-throughput screening); and
- Manufacturing of a product for sale.
Except for the license grant, any and all rights to the Product, Progeny, Modifications or Unmodified Derivatives thereof, shall remain in Cellecta. No ownership rights are transferred. Data generated by the Customer using the Product, Progeny, Modifications or Unmodified Derivatives thereof, are owned by the Customer, subject to the use restrictions above.
Customer shall have no right to transfer or grant sub-licenses under this license. The Product, Progeny, Modifications or Unmodified Derivatives thereof, licensed to the Customer must at all times remain in the possession of the Customer.
For more information, please see our press release: https://www.prnewswire.com/news-releases/ers-genomics-and-cellecta-inc-sign-license-agreement-on-crisprcas9-genome-editing-patents-for-tools-and-services-300553863.html.